Methodology · v3.2

CTSRSuccès des essais cliniques

Phase 1→2 and Phase 2→3 progression rate for {legal_name}'s OWN pipeline. EXTRACTION RULES: Extract ONLY a {legal_name}-SPECIFIC progression rate explicitly stated in a primary source (the company's own pipeline disclosure / clinicaltrials.gov outcomes for the company's OWN NCT records). Do NOT substitute an industry-average / BIO Industry Analysis benchmark for the company figure (CLAUDE.md #5 peer-substitute prohibition), and do NOT estimate or extrapolate a % from a tiny pipeline. Cite clinicaltrials.gov for the company's own trials; BIO Industry Analysis may be cited ONLY as context, never as the scored value. Return exact_numerical{value: <pct>, unit: "percent"}. ZERO-IS-ABSENT: if no company-specific progression rate is disclosed, return absent (not_disclosed) — NEVER return 0 (a 0% read is a failed/empty extraction, not a real measured rate). Ratio_band (<10→25, 10-20→55, 20-35→75, 35+→90).